86 related articles for article (PubMed ID: 15721450)
1. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation".
Menczer J
Gynecol Oncol; 2005 Mar; 96(3):906-7; author reply 907. PubMed ID: 15721450
[No Abstract] [Full Text] [Related]
2. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
Søgaard CH; Lindegaard JC; Havsteen H; Nielsen OS; Mogensen O
Gynecol Oncol; 2005 May; 97(2):410-2. PubMed ID: 15863138
[TBL] [Abstract][Full Text] [Related]
3. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
[TBL] [Abstract][Full Text] [Related]
4. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
Prat A; Parera M; Del Campo JM
J Clin Oncol; 2008 Apr; 26(10):1771-2; author reply 1772. PubMed ID: 18375912
[No Abstract] [Full Text] [Related]
6. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
7. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
[TBL] [Abstract][Full Text] [Related]
9. [Contribution of dynamic interpretation of CA 125 measurements to the understanding of an atypical clinical case].
Riedinger JM; Mousseau M; Gauchez AS
Ann Biol Clin (Paris); 2008; 66(3):333-40. PubMed ID: 18558573
[TBL] [Abstract][Full Text] [Related]
10. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
11. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
12. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
14. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
15. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
[TBL] [Abstract][Full Text] [Related]
16. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
17. Cancer antigen 125 and prognosis.
Høgdall E
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):4-8. PubMed ID: 18196998
[TBL] [Abstract][Full Text] [Related]
18. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
20. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
